Who We Are

ExosomePlus was founded in 2018 to drive an extracellular vesicle
(EV) revolution, bringing the best EV isolation and characterization
platform in the field of regenerative therapy to bear on research
wide challenges faced by pharmaceutics industry.

Moving discovery from the lab to the real world, ExosomePlus are forming strategic partnerships to help
companies integrate high purity exosomes into targeting for greater efficacy, versatility and results.
Our decade of directed exosome and its application R&D before establishment have resulted in
more than 10 patents and applications. With a majority of our professional staff and managements,
advisory board members having doctoral or other higher degrees, our employees bring extensive experience
in our target markets. ExosomePlus draws on these human resources to serve the needs of industry leaders
in medical science with our core technology capabilities.